Dr. Xiangming Lao 劳向明
Chief Physician
Hepatobiliary and Pancreatic Surgery (II), Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical and comprehensive treatment of pancreatic, biliary, ampullary, duodenal, splenic, and liver tumors. Expertise includes tumor immunotherapy and multimodal care for digestive system malignancies.
Dr. Lao holds an MD and PhD from Sun Yat-sen University. After working at Sun Yat-sen University Cancer Center since 2001, Dr. Lao was a visiting scholar at the University of Michigan (2009–2010). With over 20 years of clinical experience, Dr. Lao focuses on surgical and comprehensive treatment of pancreatic, biliary, and liver cancers. Research interests include tumor immunology, with publications in journals such as Cancer Discovery and Gastroenterology.
Professional roles
- Chair, Youth Committee of Pancreatic Cancer Professional Committee, Guangdong Anti-Cancer Association
- Vice Chair, Pancreatic Disease Professional Committee, Guangdong Health Management Association
- Vice Chair, Tumor Prevention and Treatment Professional Committee, Guangdong Health Management Association
- Standing Committee Member, Surgical Physician Branch, Guangdong Medical Doctor Association
Name order: in Chinese the family name comes first (Lao Xiangming). Papers usually list the name as Xiangming Lao or Lao X.
Selected publications
42 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- Mol Ther, 2026 (senior author): BCAT1-elicited branched-chain amino acid catabolism fosters neutrophil-mediated pan-metastasis in pancreatic cancer. PubMed 41635084
- Gastroenterol Rep (Oxf), 2020 (senior author): Impact of overweightness and critical weight loss on overall survival in patients with hepatocellular carcinoma initially treated with chemoembolization. PubMed 32280472
- Cancer Med, 2019 (senior author): Clinical conditions and treatment requirements for long-term survival among hepatitis B-related hepatocellular carcinoma initially treated with chemoembolization. PubMed 31313476
- Dig Dis Sci, 2019 (senior author): Effect of Nucleos(t)ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma. PubMed 30815819
- J Immunother, 2017 (senior author): Transforming Growth Factor β is a Poor Prognostic Factor and Inhibits the Favorable Prognostic Value of CD8+ CTL in Human Hepatocellular Carcinoma. PubMed 28394813
- Oncoimmunology, 2016 (senior author): Peritumoral stromal neutrophils are essential for c-Met-elicited metastasis in human hepatocellular carcinoma. PubMed 27853643
- Chin J Cancer, 2016 (senior author): Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection. PubMed 26992891
- Asia Pac J Clin Oncol, 2013 (first author): Hepatitis B virus reactivation and liver function after chemoembolization for hepatocellular carcinoma: How is it different from systemic chemotherapy?. PubMed 24131744
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion